论文部分内容阅读
应用酶联免疫吸附法（ELISA）测定了68例Graves病（GD）患者和20例健康对照者血清白介素6（IL－6）和可溶性白介素6受体（sIL-6R）含量。结果表明：（1）GD患者未治疗组、部分缓解组和缓解组血清IL－6水平分别高于健康对照组；（2）GD患者未治疗组、部分缓解组血清sIL－6R水平分别高于缓解组和健康对照组；（3）血清IL－6与sIL-6R之间无相关关系。提示血清IL－6和sIL-6R参与GD的发病过程，对其检测具有监测GD病情的价值。
Serum levels of interleukin 6 (IL-6) and soluble interleukin 6 receptor (sIL-6R) were measured in 68 patients with Graves disease (GD) and 20 healthy controls by enzyme-linked immunosorbent assay (ELISA) The results showed that: (1) Serum IL-6 levels in untreated group, partial remission group and remission group were higher than those in healthy control group respectively; (2) Serum sIL-6R levels in untreated group and partial remission group were higher than those in GD group Remission group and healthy control group; (3) serum IL-6 and sIL-6R no correlation between. It is suggested that serum IL-6 and sIL-6R are involved in the pathogenesis of GD, and their value of monitoring the status of GD may be detected.